# Wearable Medical Device Market

> Wearable Medical Device Market Research Report By Device Type (Fitness Trackers, Smartwatches, Medical Monitors, Wearable ECG Monitors, Wearable Blood Pressure Monitors), By Technology (Biosensors, Microcontrollers, Flexible display, Wireless Communication, Power Management), By Application (Chronic Diseases Management, Fitness Wellness, Elderly Care, Remote Patient Monitoring, Health Analytics), By End User (Hospitals, Home Healthcare, Ambulatory Surgical Centers, Fitness Centers, Individual Consumers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 14.2%
- **2025:** USD 44.5 Billion
- **2035:** USD 167.8 Billion
- **Key Players:** Apple Inc., Abbott Laboratories, Dexcom Inc., Medtronic plc, Garmin Ltd., Samsung Electronics, Philips N.V., Omron Healthcare

**Report ID:** MRFR/MED/0397-CR · **Pages:** 200 · **Author:** Snehal Singh & Kinjoll Dey · **Last Updated:** July 12, 2026

**URL:** https://www.marketresearchfuture.com/reports/wearable-medical-device-market-899

---

## Market Summary

As per Market Research Future Reports analysis, the Wearable Medical Device Market size was valued at USD 45.09 Billion in 2024. The market is projected to grow from USD 49.97 Billion in 2025 to USD 139.6 Billion by 2035, exhibiting a CAGR of 10.82% during the forecast period 2025–2035. North America led the market with over 39.92% share, generating around USD 18 billion in revenue.
 
The Wearable Medical Device Market is primarily driven by increasing demand for continuous health monitoring and preventive healthcare, supported by technological advancements and rising consumer awareness, enabling real-time tracking of vital parameters and improved management of chronic diseases globally.
 
According to the Centers for Disease Control and Prevention (CDC), 6 in 10 adults globally suffer from at least one chronic disease, increasing the need for continuous monitoring solutions. This drives adoption of wearable medical devices for early detection, real-time tracking, and improved long-term disease management outcomes.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Expanded Medicare/Medicaid reimbursement for connected diagnostics | +2.8% | North America | Short-term (≤2 yr) | [2] |
| EU Digital Health Strategy funding and MDR fast-track | +2.1% | Europe | Medium-term (2–4 yr) | [1] |
| Miniaturized biosensor and flexible-battery innovations | +2.4% | Global | Long-term (≥4 yr) | [11] |
| Smartphone-ecosystem integration (HealthKit, Health Connect) | +1.6% | Global | Short-term (≤2 yr) | [4] |
| Chronic-disease prevalence growth (diabetes, CVD, COPD) | +1.9% | Global | Long-term (≥4 yr) | [12] |
| Asia-Pacific government digitization mandates | +1.5% | Asia-Pacific | Medium-term (2–4 yr) | [10] |
| Direct-to-consumer subscription models | +1.2% | North America, Europe | Medium-term (2–4 yr) | [13] |

### Reimbursement Expansion in the United States

Medicare's Physician Fee Schedule has been systematically updated to integrate Remote Patient Monitoring (RPM) as a standard clinical practice. By providing specific CPT codes for device setup (99453), monthly monitoring (99454), and professional treatment management (99457, 99458), the Centers for Medicare & Medicaid Services (CMS) has established a scalable financial framework. This shift enables providers to bill for continuous data oversight for patients with acute or chronic conditions, effectively transitioning wearable technology from elective consumer health tools into integral components of reimbursable, value-based care delivery models.

### Miniaturized Biosensors and Flexible Batteries

Advancements in materials science are enabling the transition toward multi-analyte, skin-interfaced platforms. By leveraging flexible electronics, thin-film substrates, and high-density power sources, developers can now integrate multiple physiological and biochemical sensing channels into a single, discreet adhesive patch. These systems allow for continuous, non-invasive monitoring of biomarkers, significantly reducing the reliance on bulky, cost-intensive bedside clinical monitoring equipment while maintaining high signal fidelity and diagnostic precision.

### Chronic-Disease Prevalence

The global burden of chronic disease is escalating, driving sustained demand for long-term health management solutions. According to the International Diabetes Federation, the number of adults (20–79 years) living with diabetes is projected to rise from 537 million in 2021 to 783 million by 2045. Concurrently, the World Health Organization identifies cardiovascular diseases as the leading cause of mortality, with approximately 20 million deaths recorded annually. This rising prevalence creates a durable, long-term requirement for continuous monitoring technologies.

## Restraints

## Restraints Impact Analysis

Impact percentages below are directional headwinds that temper, but do not reverse, the positive growth trajectory. They reflect regulatory, clinical, and supply-chain frictions identified through primary research.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Data privacy and cybersecurity compliance costs | –1.4% | Global | Long-term (≥4 yr) | [14] |
| Physician skepticism toward consumer-grade accuracy | –1.1% | North America, Europe | Medium-term (2–4 yr) | [15] |
| Fragmented international regulatory frameworks | –0.9% | Global | Long-term (≥4 yr) | [9] |
| Reimbursement lag in emerging markets | –0.8% | South America, MEA | Medium-term (2–4 yr) | [16] |
| Semiconductor and rare-earth supply-chain volatility | –0.6% | Asia-Pacific | Short-term (≤2 yr) | [17] |

### Cybersecurity and Data-Privacy Overhead

The healthcare sector consistently faces the highest average data breach costs, reaching $10.93 million per incident, according to recent industry analysis. Furthermore, stringent regulations like the EU's Cyber Resilience Act, which entered into force in December 2024, mandate rigorous lifecycle security and vulnerability management for connected devices. Compliance costs are escalating as manufacturers must now incorporate comprehensive cybersecurity frameworks to avoid significant regulatory penalties.

### Physician Adoption Barriers

Integrating wearable-sourced data into clinical workflows remains a significant hurdle. Research indicates that while wearable usage among U.S. adults rose to 41% by 2024, clinicians lack standardized procedures to utilize this information effectively. Skepticism persists regarding data accuracy and motion artifacts, with many physicians awaiting formal, validated clinical-practice guidelines from professional medical societies before relying on these tools for critical diagnostic decisions.

## Opportunities

## Wearable Medical Device Market Opportunities

### Hospital-at-Home Program Scaling

The Centers for Medicare & Medicaid Services (CMS) has expanded the Acute Hospital Care at Home (AHCAH) initiative, with 366 hospitals across 139 health systems approved as of early 2026. This model necessitates continuous physiological monitoring to maintain clinical standards outside traditional settings. The recent legislative extension of these waivers through September 2030 provides the regulatory certainty required for sustained, long-term medical device procurement.

### Prescription Digital Therapeutics Convergence

The FDA’s Digital Health Center of Excellence is actively streamlining regulatory pathways for combination products that integrate hardware-based wearables with software-driven therapeutic interventions. By fostering a framework for "Software as a Medical Device" (SaMD) and real-world evidence evaluation, the agency is enabling manufacturers to pursue hybrid revenue models, combining initial device sales with recurring licensing for data-driven, prescription-grade digital health services.

### Emerging-Market Insurance Expansion

India’s Ayushman Bharat Digital Mission (ABDM) has established a massive digital infrastructure, linking over 104 crore health records to 93 crore Ayushman Bharat Health Accounts as of July 2026. This interoperable backbone allows insurers and providers to integrate wearable-sourced vitals into official medical histories. Similar initiatives in other emerging economies are standardizing data formats, enabling wearables to transition from cash-only consumer goods to reimbursed assets.

### Wearable-Data Monetization and Analytics Platforms

The aggregation of high-fidelity, de-identified biosignal data is creating new value for decentralized [clinical trials](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787) and population health management. Pharmaceutical and insurance entities are increasingly seeking longitudinal datasets to refine risk-stratification models and drug efficacy monitoring. For device manufacturers, licensing these anonymized streams provides a scalable secondary revenue channel, enhancing overall gross margins through software-based analytics and predictive health insights.

### Geriatric Fall-Detection and Remote Elder Care

Falls are a critical public health concern; research indicates that over 36 million falls occur annually among older adults, with roughly 37% resulting in injuries necessitating professional medical treatment. Wearable accelerometers utilizing edge-AI classification are evolving into clinical safety tools. Supported by specialized billing codes, these devices are increasingly integrated into remote monitoring protocols to provide proactive, continuous geriatric fall detection and prevention.

## Future Outlook

## Wearable Medical Device Market Future Outlook

### AI-Driven Predictive Diagnostics

Artificial intelligence integration is accelerating as healthcare organizations prioritize clinical-grade predictive tools. Recent industry data indicates that 86% of healthcare organizations are currently integrating AI into their operational or clinical workflows to improve diagnostic accuracy. By leveraging on-device inference engines, manufacturers are shifting from simple data-capture devices toward autonomous systems that provide real-time, actionable insights, reducing latency and reliance on cloud-based processing.

### Platform Economics and Subscription Revenue

The business model for medical wearables is undergoing a significant transition from one-time unit sales to recurring, service-oriented revenue streams. Manufacturers are increasingly adopting "Hardware-as-a-Service" frameworks, which bundle sensor hardware with ongoing data analytics, remote monitoring, and personalized coaching. This shift stabilizes long-term income, as companies prioritize high-margin digital health subscriptions to complement their diagnostic hardware, ensuring sustainable financial growth.

### Sustainability and Circular-Design Mandates

The European Union’s Ecodesign for Sustainable Products Regulation, which entered into force in July 2024, is establishing new global benchmarks for medical device design. By mandating enhanced durability, reparability, and material circularity, the regulation forces manufacturers to prioritize sustainable production. Companies that proactively integrate modular, recyclable components and eco-conscious manufacturing processes will secure a distinct regulatory and competitive advantage in the European market.

### Decentralized Clinical Trials

The landscape of pharmaceutical research is rapidly evolving, with decentralized clinical trials (DCTs) becoming a standard for efficient patient engagement. Following the FDA’s December 2023 guidance on Digital Health Technologies for Remote Data Acquisition, sponsors have a clear regulatory path for using wearable-acquired data as valid endpoints. This framework facilitates the shift toward home-based trial participation, significantly expanding the reach and accessibility of trials.

## Segment Insights

## Wearable Medical Device Market Segmentation

### By Device Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Diagnostic & Monitoring Devices | 67.5% share (2025) | CGM, ECG patches, SpO₂ wearables |
| Therapeutic Devices | 17.0% CAGR (2026–2035) | Insulin pumps, neurostimulation patches |

Diagnostic and monitoring devices dominate the Wearable Medical Device Market, anchored by continuous glucose monitors that generated over USD 9 billion globally in 2024 and ambulatory ECG patches adopted across 4,200+ U.S. cardiology practices. Therapeutic devices are the faster-growing category as closed-loop insulin delivery systems and transcutaneous electrical nerve stimulation wearables gain reimbursement approval in the U.S. and EU [[6]](https://abbott.com)[[7]](https://dexcom.com).

### By Age Group

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Adults (18–60) | 56.8% share (2025) | Chronic-disease management, workplace wellness |
| Seniors (60+) | USD 13.2 Billion (2025) | Fall detection, cardiac monitoring |
| Under 18 | 17.5% CAGR (2026–2035) | Pediatric diabetes CGM, asthma monitors |

Adults aged 18–60 represent the core purchasing demographic in the Wearable Medical Device Market, driven by employer-sponsored wellness programs and direct-to-consumer smartwatch ECG features. The under-18 cohort is expanding fastest as pediatric endocrinologists increasingly prescribe CGM systems for Type 1 diabetes management and regulatory bodies approve child-sized form factors [[12]](https://diabetesatlas.org).

### By Distribution Channel

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Offline (Pharmacy & Prescription) | 57.8% share (2025) | Physician-prescribed devices, insurance formularies |
| Online (DTC & E-pharmacy) | 16.7% CAGR (2026–2035) | Subscription refills, telehealth bundling |

Offline channels—pharmacies and prescription-based distribution—hold a commanding 57.8% share in 2025, underpinned by physician-prescribed devices and insurance formulary requirements. Online channels, encompassing DTC and e-pharmacy models, are growing much faster at a 16.7% CAGR through 2035, fueled by subscription refill programs and telehealth bundling. This gap points to a market still anchored in clinical gatekeeping today, but rapidly evolving toward direct-to-consumer convenience.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Home Healthcare | 55.4% share (2025) | Post-discharge monitoring mandates |
| Sports & Fitness | 14.7% CAGR (2026–2035) | Consumer performance tracking, coach-led analytics |
| Clinical / Hospital Use | USD 8.9 Billion (2025) | ICU step-down and ambulatory surgery centers |

Home healthcare leads application-based demand with a 55.4% share in 2025, driven by mandates for post-discharge patient monitoring. Sports and fitness applications are expanding fastest at a 14.7% CAGR through 2035, as consumers and coaches increasingly rely on performance tracking and data-driven analytics. Clinical and hospital use, valued at USD 8.9 billion, remains a steady contributor, anchored by ICU step-down care and the growing volume of ambulatory surgery centers.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Consumers | 58.9% share (2025) | Smartwatch health features, DTC marketing |
| Hospitals & Clinics | 16.3% CAGR (2026–2035) | RPM reimbursement codes, value-based care |
| Research Institutions | USD 2.1 Billion (2025) | Decentralized clinical-trial endpoints |

Consumers represent the largest end-user segment at 58.9% share in 2025, propelled by smartwatch health features and direct-to-consumer marketing strategies. Hospitals and clinics are poised for the fastest growth at a 16.3% CAGR through 2035, as reimbursement codes for remote patient monitoring and the shift toward value-based care accelerate institutional adoption. Research institutions, valued at USD 2.1 billion, play a growing role as decentralized clinical trials increasingly rely on wearable-generated endpoints.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 36.5% share (2025) | RPM reimbursement, hospital-at-home mandates |
| Europe | 25.5% share (2025) | MDR compliance, aging-population programs |
| Asia-Pacific | 17.3% CAGR (2026–2035) | Government digitization, manufacturing cost advantage |
| South America | USD 3.34 Billion (2025) | Insurance digitization, chronic-disease burden |
| Middle East & Africa | 6.0% share (2025) | Gulf sovereign health funds, mobile-first adoption |
| Total | USD 44.5 Billion (2025) | — |

The Wearable Medical Device Market exhibits distinct regional dynamics shaped by payer structures, regulatory maturity, and digital-health infrastructure readiness.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 79.2% of regional share | CMS reimbursement expansion |
| Canada | 12.8% of regional share | Provincial telehealth mandates |
| Mexico | 8.0% of regional share | IMSS digital enrollment program |

The United States accounts for the bulk of North American demand in the Wearable Medical Device Market, propelled by CMS remote-monitoring codes and a dense network of integrated delivery systems that co-invest with device OEMs. Canada's provincial health authorities approved wearable CGM reimbursement in Ontario and British Columbia during 2024, while Mexico's IMSS is piloting wearable-based chronic-disease management in 14 metropolitan zones [[2]](https://cms.gov)[[16]](https://who.int).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 15.3% CAGR | DiGA digital-health-app reimbursement |
| United Kingdom | USD 2.45 Billion (2025) | NHS Long-Term Plan wearable integration |
| France | 14.8% CAGR | Ségur du Numérique interoperability funding |
| Italy | 12.1% of regional share | National Recovery and Resilience Plan |
| Spain | 9.4% of regional share | SNS telemedicine expansion |
| Nordic Countries | 14.9% CAGR | High digital literacy and public-payer adoption |
| Russia | 5.8% of regional share | Domestic manufacturing incentives |
| Rest of Europe | 11.2% of regional share | Varied regulatory alignment timelines |

Germany's DiGA fast-track pathway has cleared over 60 digital health applications since 2020, several of which require companion wearable hardware, making it the regulatory pacesetter within Europe's share of the Wearable Medical Device Market. The UK's NHS Long-Term Plan earmarked GBP 1.8 billion for digital transformation, explicitly referencing wearable-sourced data in cardiology and diabetes care pathways [[9]](https://eur-lex.europa.eu)[[1]](https://ec.europa.eu).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 31.4% of regional share | NMPA fast-track and domestic sensor IP |
| India | 18.2% CAGR | Ayushman Bharat Digital Mission |
| Japan | USD 2.18 Billion (2025) | Super-aged society and nursing shortage |
| South Korea | 16.5% CAGR | MFDS SaMD regulatory reform |
| ASEAN | 15.8% CAGR | Mobile-first healthcare leapfrogging |
| Rest of Asia-Pacific | 8.6% of regional share | Fragmented regulatory landscape |

China's NMPA issued expedited review guidelines for Class II wearable diagnostics in 2024, cutting approval timelines from 18 to 9 months and attracting both domestic champions and multinational entrants to the region's rapidly expanding slice of the Wearable Medical Device Market. India's target of 500 million linked health records by 2028 under Ayushman Digital creates the infrastructure backbone that makes continuous wearable monitoring reimbursable at scale [[10]](https://nha.gov.in).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.3% of regional share | SUS digital integration |
| Argentina | 15.7% CAGR | Private-sector health-tech investment |
| Rest of South America | 14.2% CAGR | Cross-border telemedicine platforms |

Brazil's Conecte SUS initiative is migrating 215 million citizens to unified digital health records, creating a pathway for wearable data to inform public-health resource allocation and chronic-disease management within the Wearable Medical Device Market's South American footprint [[16]](https://who.int).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.5% of regional share | Vision 2030 health-tech investment |
| UAE | 24.1% of regional share | Smart Dubai and DHA digital mandates |
| South Africa | 15.6% CAGR | Private hospital chain procurement |
| Egypt | 13.8% CAGR | Universal Health Insurance digitization |
| Rest of MEA | 19.9% of regional share | NGO-funded maternal/child health wearables |

Saudi Arabia's Vision 2030 allocated SAR 12 billion to health-sector digitization, explicitly funding wearable-based population screening programs for diabetes and hypertension. The UAE's Dubai Health Authority mandated interoperable wearable-data feeds into its Salama electronic health record system in 2024, reinforcing the region's commitment within the Wearable Medical Device Market [[16]](https://who.int).

## Competitive Benchmarking

## Competitive Benchmarking

The Wearable Medical Device Market exhibits low concentration, with the top five players collectively holding an estimated 32–38% revenue share. The Herfindahl-Hirschman Index sits below 800, confirming a fragmented landscape where established med-tech incumbents compete alongside consumer-electronics giants and venture-backed sensor startups. Innovation velocity and regulatory clearance pipelines, rather than scale alone, determine competitive positioning.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Apple Inc. | 8–11% | Apple Watch ECG, SpO₂, temperature sensing | Consumer-ecosystem gateway to clinical data |
| Abbott Laboratories | 7–10% | FreeStyle Libre CGM family | Category leader in continuous glucose monitoring |
| Dexcom Inc. | 5–8% | G7 CGM, Stelo biosensor | Pharmacy-channel CGM expansion |
| Medtronic plc | 4–7% | Guardian CGM, MiniMed insulin pump | Closed-loop therapeutic integration |
| Garmin Ltd. | 3–5% | Venu series, Vivosmart | Fitness-to-clinical crossover strategy |
| Samsung Electronics | 3–5% | Galaxy Watch BIA, ECG, BP | Android ecosystem health platform |
| Philips N.V. | 3–5% | BioIntelliSense partnership, patient patches | Hospital-grade wearable monitoring |
| Omron Healthcare | 2–4% | HeartGuide BP watch, VitalSight | Hypertension-focused connected devices |
| Masimo Corporation | 2–4% | Masimo W1 watch, MightySat | Hospital-to-consumer accuracy bridge |
| Fitbit (Google) | 2–4% | Fitbit Sense, Pixel Watch health suite | Population-health data analytics |

## Recent News & Developments

## Recent News & Developments

- Medtronic(June 15, 2026): Medtronic finalized its acquisition of Scientia Vascular, integrating specialized neurovascular technologies to enhance its portfolio for complex medical procedure navigation.
- Zimmer Biomet(June 30, 2026): Zimmer Biomet announced a definitive agreement to acquire Pacira BioSciences’ iovera system, expanding its surgical portfolio with non-opioid cold therapy technology.
- Danaher(June 11, 2026): Danaher completed the $9.9 billion acquisition of Masimo, transitioning the company into an autonomous business unit within Danaher's medical diagnostics segment.

## Report Scope

## Wearable Medical Device Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Wearable Medical Device Market, encompassing diagnostic, monitoring, and therapeutic wearable devices |
| Study Period | 2021–2035 |
| CAGR | 14.2% (2026–2035) |
| Market Size (2025) | USD 44.5 Billion |
| Market Size (2035) | USD 167.8 Billion |
| Fastest Growing Segment | Therapeutic devices (17.0% CAGR); Under-18 age group (17.5% CAGR) |
| Companies Profiled | 10 (Apple, Abbott, Dexcom, Medtronic, Garmin, Samsung, Philips, Omron, Masimo, Fitbit/Google) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do wearable medical devices handle data interoperability across hospital EHR systems?**
A: Most FDA-cleared wearables now support HL7 FHIR APIs, enabling bidirectional data exchange with Epic, Cerner, and MEDITECH platforms. FHIR-based integration has reduced onboarding time from months to weeks at 1,200+ U.S. health systems [8].

**Q: What battery technologies are most likely to displace lithium coin cells in next-generation medical wearables?**
A: Solid-state thin-film batteries and zinc-air micro-cells are leading candidates, offering 40% higher energy density at half the volume. Commercial availability is expected by 2028 [11].

**Q: How are insurers incorporating wearable data into underwriting and premium models?**
A: Select U.S. and European life insurers offer 5–15% premium discounts for policyholders sharing continuous wearable health metrics. Actuarial models weighting wearable-sourced resting heart rate and activity data are in pilot at six major carriers [13].

**Q: What role do wearables play in decentralized clinical trials for pharmaceutical sponsors?**
A: Wearable endpoints replace in-clinic visits for vitals collection, reducing trial dropout rates by 18–22%. The FDA's 2023 guidance formally recognizes wearable-derived digital biomarkers as primary or secondary endpoints [20].

**Q: How do cybersecurity requirements differ between consumer wellness bands and clinical-grade wearable devices?**
A: Clinical-grade devices must comply with FDA premarket cybersecurity guidance and IEC 62443, requiring threat modeling, software bill of materials, and coordinated vulnerability disclosure — obligations absent from consumer wellness products [14].

**Q: What procurement criteria should hospital systems prioritize when evaluating the Wearable Medical Device Market?**
A: Prioritize EHR integration readiness, sensor accuracy validation per ISO 81060 or IEC 60601, and vendor-managed device lifecycle services. Total cost of ownership over three years matters more than unit price [15].

**Q: Which emerging use cases could reshape the Wearable Medical Device Market beyond traditional vital-sign monitoring?**
A: Continuous medication-adherence tracking via ingestible-sensor-paired wearables and sweat-based biomarker panels for early cancer screening are advancing through Phase II clinical validation. Both could reach commercial availability by 2030 [11][20].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/wearable-medical-device-market-899*